Choose Cresp® for Long-term Efficacy in ND-CKD

H2 tag- SEO Purpose

eGFR: Estimated glomerular filtration rate; Hb: Hemoglobin; SD: Standard deviation.

Cresp logo
Non-dialysis chronic kidney disease (ND-CKD) patients were treated with Darbepoetin Alfa and followed up for 36 months.

Non-dialysis chronic kidney disease (ND-CKD) patients were treated with Darbepoetin Alfa and followed up for 36 months.

Mean Hb levels in Darbepoetin Alfa treated ND-CKD patients remained between 10 g/dL and 10.6 g/dL, In Darbepoetin Alfa treated ND-CKD patients eGFR remained almost constant throughout the study
Safety analysis

Safety analysis

Incidence rate of ADRs in the present study (7.1%) was lower than that reported in pre-approval Japanese clinical trials (30.75%)

Incidence rate of ADRs in the present study (7.1%) was lower than that reported in pre-approval Japanese clinical trials (30.75%)

Darbepoetin Alfa can effectively maintain Hb levels and is safe for ND-CKD patients

Cresp 2

Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Cresp